• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Q&A: Jade CEO talks about re­verse merg­er and IgAN drugs

6 months ago
Startups
Deals

Gar­dasil de­mand in Chi­na sinks, and Mer­ck ex­pects the same next quar­ter

6 months ago
China
Pharma

WuXi in ‘ear­ly stages’ of CGT busi­ness re­view; Lon­za ex­ec be­comes AGC Bio CEO

6 months ago
Manufacturing

Take­da says mul­ti­year re­struc­tur­ing is 'on track'

6 months ago
R&D
Pharma

Ar­genx re­ports Vyv­gart sales streak, bol­stered by launch in rare neu­ro dis­or­der

6 months ago
Pharma

Boehringer, Gubra stop work on obe­si­ty drug; Gala­pa­gos restarts CAR-T study

6 months ago
News Briefing

Why a promi­nent health tech VC keeps ad­just­ing how it thinks about AI in health­care

6 months ago
AI
Health Tech

Evom­mune rais­es $115M for I&I pipeline and pre­pares for Phase 2 re­sults

6 months ago
Financing
Startups

Ab­b­Vie adds to T cell en­gager mo­men­tum, with EvolveIm­mune pact start­ing at $65M

6 months ago
Startups
Deals

An­oth­er Paragon off­shoot inks re­verse merg­er as Jade takes Aerovate’s place

6 months ago
Startups
Deals

Am­gen makes pipeline cuts, but obe­si­ty plans re­main the fo­cus

6 months ago
R&D

'What are we go­ing to stop?' Top Wal­greens ex­ec lays out the fu­ture of its health­care busi­ness

6 months ago
Health Tech

Bris­tol My­ers ups rev­enue guid­ance again, rais­ing con­fi­dence in cost-cut­ting

6 months ago
Pharma

Cor­cept miss­es pri­ma­ry end­point in sup­port­ive Cush­ing's syn­drome study

6 months ago
R&D

Com­pass Path­ways de­lays key Phase 3 psilo­cy­bin read­outs, spurring 30% lay­offs

6 months ago
R&D

Lex­eo shares ear­ly da­ta on Alzheimer’s gene ther­a­py 

6 months ago
R&D

Roche presents ear­ly-stage re­sults for lat­est amy­loid-based Alzheimer's at­tempt

6 months ago
R&D

Ab­b­Vie’s im­munol­o­gy block­busters make up for Hu­mi­ra sales drop in Q3

6 months ago
Pharma

At­las of tu­mors re­veals in 3D how cells change in­to can­cer

6 months ago
R&D
Discovery

Hints of im­pa­tience grow with Bio­gen as it tries to find a bridge to growth

6 months ago
R&D
Pharma

FDA says all ver­sions of Novo's GLP-1 weight loss drugs are now avail­able

6 months ago
FDA+

As­traZeneca Chi­na ex­ec probed by lo­cal au­thor­i­ties

6 months ago
China
Law

GSK cuts 24-va­lent pneu­mo­coc­cal pro­gram for adults due to com­pe­ti­tion

6 months ago
R&D

Leal Ther­a­peu­tics rais­es $45M; Syn­Ox adds to Se­ries B

6 months ago
News Briefing
First page Previous page 71727374757677 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times